UK prescription product trends: annual review 2017

As the first point of call for companies needing to communicate their product updates to prescribers, MIMS is uniquely placed to observe trends in the pharmaceutical marketplace.

In this report available exclusively to MIMS corporate subscribers, we review the branded products added to MIMS in 2017, analysing them by classification, route of administration, company, therapeutic area, indication, molecule type, pharmacological class, active ingredients and novelty. As a reference point, we compare the findings with data from 2016.

We highlight the new small molecules and biologics that were added to MIMS in 2017, including several entirely new pharmacological classes.

In addition, we review the products that were removed from MIMS in 2017 and outline some new products expected to launch in 2018.

MIMS corporate subscribers can access the report using the password provided by email.